Research & Resources
Science
Key Research & Landmark Studies
ME/CFS research accelerated dramatically after 2020, driven by the long COVID pandemic. Here are the most significant scientific milestones through April 2026.
- ME/CFS has been classified as a neurological disease by the WHO since 1969, when myalgic encephalomyelitis was listed in ICD-8. Chronic fatigue syndrome was not introduced as a name until 1988.[108,109]
- The 2023 WASF3 discovery was the first molecular mechanism explaining PEM.
- DecodeME (2025) is the largest ME/CFS genetic study ever - 15,500+ patients - pointing to synaptic and neurological gene networks.
- 2025 International Declaration signed by 65+ researchers from 14 countries formally rejected the psychosocial model.
- The NIH ME/CFS Research Roadmap (2024) prioritizes chronic infections, immune exhaustion, and CNS pathology for accelerated trials.
2003 - Canadian Consensus Criteria (CCC)
First criteria to make PEM and neurological/immune features central to diagnosis. Became the gold standard for research and specialist practice. Authored by Carruthers et al.
2006 - Hickie et al. (BMJ) Prospective Cohort
Landmark study showing post-infectious ME/CFS occurs after EBV, Ross River virus, and Coxiella (Q fever) at comparable rates (~12%), demonstrating ME/CFS is a genuine post-infectious syndrome regardless of pathogen.
2014 - Nakatomi et al. PET Neuroinflammation Study
First rigorous PET imaging study documenting neuroinflammation in ME/CFS brains - particularly in the thalamus, midbrain, and cingulate cortex - correlating with symptom severity.
2015 - IOM "Beyond ME/CFS" Report & SEID
Institute of Medicine concluded ME/CFS is a serious, chronic, complex systemic disease; proposed new diagnostic criteria (SEID) and called for urgent research investment. A watershed moment in legitimizing ME/CFS in mainstream medicine.
2019 - RituxME Trial (Fluge, Mella et al., Annals of Internal Medicine)
Randomized trial of rituximab (anti-CD20 B-cell depletion) - negative in full population but demonstrated subgroups with autoantibodies showed benefit, directing future research toward autoimmune subsets.
2021 - NICE Guidelines Remove CBT/GET
UK National Institute for Health and Care Excellence formally removed Graded Exercise Therapy and CBT (as curative treatment) from ME/CFS management guidelines, citing evidence of harm. Major vindication for patient advocates.
2023 - WASF3 Discovery (Wang, Hwang et al., PNAS)
Identified WASF3 protein as a key disruptor of mitochondrial Complex I in ME/CFS muscle tissue. Provides a molecular mechanism for exercise intolerance and energy failure. Widely considered a breakthrough.
2024 - NIH Deep Phenotyping Study (Nath, Walitt et al., Nature Communications)
Most intensive biological characterization of post-infectious ME/CFS yet - documented multiple biological abnormalities in carefully phenotyped participants, providing crucial objective evidence of disease biology.
2024 - DecodeME Genome-Wide Association Study
Largest genetic study of ME/CFS (15,579 patients vs. 259,909 controls) identified 29 genetic variants linked to ME/CFS, relating to immune dysregulation, autoimmunity, antiviral immunity, neurological function, and mitochondria - confirming the genetic and biological basis of the disease.
2024 - NINDS ME/CFS Research Roadmap Finalized
NIH established eight priority research areas: chronic infections, immune system, nervous system, cardiovascular circulation, metabolism, physiology, less-studied pathologies, and genomics - with explicit goal of accelerating clinical trials by 2025.
2025 (Feb) - Charité Mitochondrial Electron Microscopy
Direct visual evidence of structurally damaged mitochondria in ME/CFS muscle biopsies, with simultaneous necrosis and regeneration. Abnormal sodium overload in muscle cells leading to calcium-mediated mitochondrial damage.
2025 - Komaroff et al. PNAS Patient-Outcome Study
Analysis of 3,900+ ME/CFS and long COVID patients identifying symptom-based subgroups with distinct treatment responses, and substantial overlap between ME/CFS and long COVID in both symptom profiles and therapeutic responses. Identified top patient-rated treatments.
2025 - IACFS/ME Conference: Immunoadsorption Results
Significant symptom improvement reported in majority of 20 patients with post-COVID ME/CFS and elevated β-adrenergic receptor antibodies treated with immunoadsorption (antibody removal). Larger Phase II RCT underway.
Name and Terminology
Patients and researchers have used many names over the decades. Today most clinicians use "ME/CFS" as an umbrella. Some prefer "ME" to emphasize the neurological features; others use "SEID" (Systemic Exertion Intolerance Disease), proposed by the 2015 Institute of Medicine report.[3] In WHO ICD-11, it appears as G93.32. The older term "CFS" is considered stigmatizing by many patients. The CDC formally adopted "ME/CFS" as the combined term in 2016.
Global & European Epidemiology: Full Statistical Picture
Prevalence estimates vary significantly by country and diagnostic criteria used. The table below consolidates data from government surveys, peer-reviewed epidemiology, and European research networks.
| Region / Country | Estimated Prevalence | Estimated Cases | Source |
|---|---|---|---|
| United States | 1.3% of adults (diagnosed) True prevalence likely higher; 90%+ undiagnosed |
~3.3 million (diagnosed) Potentially 17M+ if all cases counted |
CDC/NCHS National Health Interview Survey 2021-22[1]; IOM 2015 range: 836,000-2.5M[3] |
| United Kingdom | ~0.2-0.4% (community); estimated 250,000 | ~250,000 | NICE NG206 2021[37]; EUROMENE estimates[58] |
| Germany | ~0.8% (estimated post-COVID inclusion) | >650,000 | ME/CFS Research Foundation prevalence and cost study, 2025[59]; German Federal Ministry of Health funding: ~€150M through 2028 |
| Netherlands | Up to 3.6% in working-age population | ~75,000-150,000 | Huibers et al., Occupational and Environmental Medicine 2004; Netherlands launched dedicated 10-year, €28.5M research program[60] |
| Sweden | ~2.6% | ~270,000 | Evengard et al., Psychological Medicine 2005; Bragee ME/CFS Center (Stockholm) is a specialist clinical hub |
| Europe (all) | 0.1-2.2% across studies; no harmonized data | ~1.5-2 million (conservative estimate) | EUROMENE Systematic Review (Estevez-Lopez et al., PMC, 2020)[61]; economic burden estimated ~€40 billion/year if UK rates extrapolated across EU[58] |
| Australia | ~0.3% (diagnosed) | ~75,000-250,000 | National Centre of Excellence in ME/CFS; Eaton-Fitch et al. 2020[56] |
| Global | 0.2-0.89% (general population) | 17-24 million; potentially 30M+ with post-COVID ME/CFS | CDC/AMMES worldwide estimate[6]; UK Biobank analysis 2018 |
Leading Researchers & Clinical Centers
The following researchers and institutions are among the most cited and clinically recognized in the ME/CFS field as of April 2026. Inclusion reflects publication record, clinical leadership, and peer recognition - not personal endorsement of all views.
Ronald W. Davis, PhD
Director of Stanford's ME/CFS Collaborative Research Center (formerly CFS Research Center). Legendary geneticist who redirected his career to ME/CFS after his son became severely ill. Primary focus: nanotechnology diagnostic tools, metabolomics, immune profiling. Affiliated with Open Medicine Foundation.[64]
Mark M. Davis, PhD
Immunologist at Stanford, co-author of landmark immune profiling studies in ME/CFS (Montoya & Davis, PNAS 2017). Contributed to the deep phenotyping of cytokine profiles across illness duration, finding IL-7 elevated in shorter-duration disease.[65]
Jose G. Montoya, MD
Infectious disease specialist who established the Stanford ME/CFS Initiative clinic. Pioneer in investigating viral triggers and antiviral approaches. Co-author of the 2021 U.S. ME/CFS Clinician Coalition guidance in Mayo Clinic Proceedings. The Stanford ME/CFS clinic (Atherton, CA) remains one of the few dedicated specialist ME/CFS clinical programs in the US.[26,66]
Lucinda Bateman, MD
Lead author of the 2021 ME/CFS Clinician Coalition guidance (Mayo Clinic Proceedings). Co-founder of the Bateman Horne Center of Excellence (Salt Lake City). Clinical expert on the 2015 IOM/NAM diagnostic criteria committee. One of the most experienced ME/CFS clinicians in the US, with 45+ published studies.[26]
Avindra Nath, MD
Chief of the NIH Section of Infections of the Nervous System. Led the landmark NIH deep phenotyping intramural study of post-infectious ME/CFS (Nature Communications, 2024). Named to TIME100 Health list 2024. Key figure in establishing ME/CFS biological evidence at the NIH.[8,9]
Carmen Scheibenbogen, MD
Professor and immunologist at Charite University Berlin. Leading researcher on GPCR autoantibodies, immunoadsorption therapy, and the autoimmune subset of ME/CFS. Director of multiple German clinical trials (IA-PACS-CFS, RIA). Key figure in European ME/CFS biomedical research.[12,39]
Maureen Hanson, PhD
Professor of molecular biology at Cornell University (not Columbia - corrected); Director of the NIH-funded ME/CFS Collaborative Research Center at Cornell focusing on metabolomics, gut microbiome, and immune profiling. Co-author of the Giloteaux microbiome study (Microbiome, 2016).[20]
Anthony Komaroff, MD
Professor Emeritus at Harvard Medical School. One of the longest-serving ME/CFS researchers. Author of the definitive 2019 JAMA review on ME/CFS pathophysiology and lead author of the landmark 2025 PNAS patient outcomes study of 3,900+ patients.[7,36]
Robert Naviaux, MD, PhD
Professor of Medicine, Pediatrics, and Pathology at UC San Diego. First author of the 2016 PNAS metabolomics study identifying a hypometabolic cell-danger response pattern in ME/CFS. Pioneer of the "dauer" metabolic hypothesis.[22]
Support
Resources & Next Steps
Finding good support, evidence-based providers, and community is an important part of navigating ME/CFS.
- #MEAction (meaction.net) is the leading US patient advocacy organization with provider resources and legislative action.
- Bateman Horne Center (batemanhornecenter.org) provides the most clinically comprehensive free patient and provider education.
- Solve ME/CFS Initiative (solvecfs.org) funds research and provides disability navigation resources.
- Phoenix Rising forums are the most active English-language patient community for practical treatment information.
- ME Research UK (meresearch.org.uk) and ME Association provide UK-focused clinical resources.
Key Organizations
- Bateman Horne Center - batemanhornecenter.org - Leading U.S. clinical center
- U.S. ME/CFS Clinician Coalition - evidence-based provider guidelines
- Open Medicine Foundation (OMF) - omf.ngo - Major research funder
- Solve ME/CFS Initiative - solvecfs.org
- ME Research UK - meresearch.org.uk
- IACFS/ME - iacfsme.org - International Association
Patient Support
- #MEAction - meaction.net - global patient advocacy
- MEpedia - me-pedia.org - patient-curated wiki
- Cort Johnson's Health Rising - healthrising.org - research news
- ME/CFS subreddit - r/cfs - active patient community
- Phoenix Rising Forums - forums.phoenixrising.me
For Healthcare Providers
- CDC ME/CFS Provider Pages - cdc.gov/me-cfs
- NICE Guideline NG206 (2021) - UK evidence-based guidelines
- Clinician Coalition Testing Recommendations (2021)
- NIH mapMECFS - Data portal for ME/CFS research
- Medscape CME on ME/CFS - accredited provider training